Bourne Partners

📊 This Week in Bourne Insights Reporting season from 1Q26 continues with earnings from companies such as Medpace Holdings and Samsung Biologics. Also, we look at potential key updates from the FDA that could influence approval timelines. 🔗 Read the full analysis in this week’s Bourne Insights: https://conta.cc/4ugNluf ✉️ Subscribe to our newsletter for emerging trends and analysis: https://lnkd.in/esa9Rtr2 For questions, reach out to our Director of Research, Donald Hooker, CFA.

Our team is excited to participate in a series of panels at the upcoming McGuireWoods LLP HCPE Conference this week. Our team members Jeremy Johnson, Carson Riley, Jake Curtis, and Ryan Silvester will bring their perspectives in both the General Session and the new Life Sciences track. Let us know if you will be attending and would like to connect! #HCPE #Healthcare #BournePartners

Today, we published a 60+ page “deep dive” research report on the use of artificial intelligence (AI) in clinical trials. We have been hearing more and more from our pharma, biotech, contract research organization (CRO), and trial site network relationships about potential opportunities to use AI to better design and execute clinical trials -- particularly as drug development becomes increasingly complex. Also, we see vertical SaaS vendors in the clinical trial space successfully using agentic AI to better leverage their proprietary data assets and accentuate their domain expertise. 📰 Read the report here: https://lnkd.in/e8eeYeyc Bourne Partners is a leading healthcare-focused investment bank, with deep transaction experience and knowledge in pharma and pharma services. For more discussion/info, please contact a member of our pharma services team Jeremy Johnson, James West, Jake Curtis or Ryan Silvester, and/or our research team led by Donald Hooker, CFA. ✉️ Subscribe to be the first to receive Bourne Partners exclusive research and reports: https://lnkd.in/esa9Rtr2

Another terrific event in London at BioTrinity 2026 hosted by BioUK. It was a pleasure to be part of the conversation and to engage with so many innovative leaders across the healthcare and life sciences landscape. We appreciate the thoughtful dialogue and for inviting James West, Managing Director at Bourne Partners, to share his perspectives with fellow panelists Michel RIVIER of Syneos Health, Birant Osman of Thermo Fisher Scientific, and Emilie Syed of Zinc, and Bharat Chudasama of Syneos Health.

📊 This week in Bourne Insights: Trends shaping healthcare Highlights include: New behavioral health access data highlights persistent parity gaps across employer-sponsored plans and where capacity is still needed. In regulatory news in the U.S., the FDA may revisit peptide restrictions this summer, reopening a fast-growing wellness and weight management category. 🔗  Read the full analysis in this week’s Bourne Insights: https://conta.cc/4sFl673 ✉️ Subscribe to our newsletter for emerging trends and analysis: https://lnkd.in/esa9Rtr2 For questions, reach out to our Director of Research, Donald Hooker, CFA.

📊 This week in Bourne Insights: We are tracking fourteen biopharma deals of $500M+ announced year‑to‑date, and eight over $1B since March, signaling a clear shift in deal momentum as pharma refocuses on pipeline expansion. We also dig into the rise of agentic AI in vertical SaaS, improving digital health funding trends, and a more moderate FY2027 HHS budget proposal. ⬇️ Check out the preview below. 🔗 Read our full take in this week's newsletter: https://conta.cc/4cIoARt ✉️ Subscribe to our newsletter for emerging trends and analysis: https://lnkd.in/esa9Rtr2 For questions, reach out to our Director of Research, Donald Hooker, CFA.

We’re pleased to welcome recent additions to the Bourne Partners team in our Charlotte and London offices. Our culture is central to Bourne Partners’ success. We’re intentional about building a team that works collaboratively and raises the bar every day. As we expand our presence across the U.S. and Europe, we’re proud that these new team members not only bring strong experience and perspectives, but also embody the values that define who we are. Welcome Olivia Baljet, Brackett Hardy, Alicia Nash, and Alexandra Walsh!

We’re pleased to share that James West, Managing Director and Head of Europe at Bourne Partners, will be speaking at the PLG Spring Event.   James will join industry peers to discuss valuation and deal economics shaping the healthcare services and life sciences landscape across Europe and global markets.    We look forward to engaging with the Pharmaceutical Licensing Group (PLG) community and continuing conversations on strategic M&A. Register to Attend Here: https://lnkd.in/e6zpSMGk

We’re looking forward to joining the McGuireWoods Healthcare & Private Equity Conference soon and are proud to serve as the Premier Partner for this year’s event. In partnership with McGuireWoods LLP, Bourne Partners is helping launch the inaugural Life Sciences track, expanding an already robust Healthcare Services focus and bringing even more opportunities for meaningful connection across the healthcare ecosystem. 📩 Our team will be on site and would welcome the chance to connect.: Banks Bourne, Jeremy Johnson, Xan Smith, Carson Riley, Aaron Olson, Jake Curtis, Ryan Silvester, Will Breeyear, Evan Goldstein, Oliver White 🔗 Register for the conference here: https://lnkd.in/ean6-ADN #HealthcarePrivateEquity #LifeSciences #HealthcareServices #MWHCPE2026 #BournePartners

We’re looking forward to attending INTERPHEX, a leading global pharmaceutical and biotechnology event, in New York City from April 21–23. If you’ll be there, we’d welcome the opportunity to connect. Be sure to reach out to our participating Bourne team, Jake Curtis and Nick Triantafyllides.